环己基-(2-二甲基氨基乙基)胺 | 99178-21-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环己基-(2-二甲基氨基乙基)胺
• 英文名称: N'-cyclohexyl-N,N-dimethyl-ethylenediamine
• 英文别名: N'-Cyclohexyl-N,N-dimethyl-aethylendiamin；N1-cyclohexyl-N2,N2-dimethylethane-1,2-diamine；N'cyclohexyl-N,N-dimethylethane-1,2-diamine；N,N-dimethyl-N'-cyclohexylethylenediamine；N'-Cyclohexyl-N,N-dimethyl-ethane-1,2-diamine；N-cyclohexyl-N',N'-dimethylethane-1,2-diamine
• CAS: 99178-21-9
• 化学式: C₁₀H₂₂N₂
• mdl: MFCD08144703
• 分子量: 170.298
• InChiKey: YIQANRYYROXQJY-UHFFFAOYSA-N

物化性质

• 沸点：
  90-93 °C(Press: 7 Torr)
• 密度：
  0.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  环己基-(2-二甲基氨基乙基)胺 在 sodium amide 、 苯 作用下， 生成 N-cyclohexyl-N-(2-dimethylamino-ethyl)-benzamide
  参考文献：
  名称：

  Takahashi et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1958, vol. 78, p. 1,3

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-n-环己基-乙酰胺 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 环己基-(2-二甲基氨基乙基)胺
  参考文献：
  名称：

  Takahashi et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1958, vol. 78, p. 1,3

  摘要：

  DOI：

文献信息

• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• New adenosine receptor ligands and uses thereof
  申请人：Domain Therapeutics

  公开号：EP2210891A1

  公开（公告）日：2010-07-28

  The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors could be beneficial.

  本发明提供了对腺苷A2A受体具有高亲和力的新化合物。它还提供了腺苷A2A受体的拮抗剂，以及它们作为药物用于治疗和/或预防部分或完全失活腺苷A2A受体信号通路可能有益的疾病和疾病，如阿尔茨海默病、帕金森病、注意力缺陷和多动症（ADHD）、亨廷顿病、神经保护、精神分裂症、焦虑和疼痛。本发明还涉及含有对腺苷A2A受体具有高亲和力的新化合物的药物组合物，以及它们用于治疗和/或预防部分或完全失活腺苷A2A受体可能有益的疾病和疾病。
• [EN] BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BENZODIOXANES DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012125598A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)的化合物：其中R1至R3、A、X和n如本文所定义。式(I)的化合物可用作白三烯A4水解酶(LTA4H)的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式(I)化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• Anion−π Catalysis on Fullerenes
  作者：Javier López-Andarias、Antonio Frontera、Stefan Matile

  DOI：10.1021/jacs.7b08113

  日期：2017.9.27

  charge-delocalized enolate tautomers by anion-π interactions. Enolate-π interactions on fullerenes are much shorter than standard π-π interactions and anion-π interactions on planar surfaces, and alternative cation-π interactions are not observed. These findings open new perspectives with regard to anion-π interactions in general and the use of carbon allotropes in catalysis.

  富勒烯上的阴离子-π 相互作用与富勒烯在催化中的应用一样缺乏探索。然而，强大的交换相关贡献和它们表面上的局部 π 孔保证了独特的选择性。为了详细说明这一承诺，附近附有叔胺。取决于它们的位置，由此产生的富勒烯阴离子过渡态的稳定性显示出加速不利的烯醇加成和对映选择性的外狄尔斯-阿尔德反应。发现的选择性与计算模拟一致，特别是关于通过阴离子-π 相互作用区分不同平面化和电荷离域的烯醇互变异构体。富勒烯上的烯醇-π相互作用比平面上的标准π-π相互作用和阴离子-π相互作用短得多，并没有观察到替代的阳离子-π 相互作用。这些发现为阴离子-π相互作用以及碳同素异形体在催化中的应用开辟了新的视角。
• Benzofuran Derivatives
  申请人：Kawaguchi Takayuki

  公开号：US20090209511A1

  公开（公告）日：2009-08-20

  The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: —N═ or —CH═; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R 1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R 3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.

  本发明提供了式[1]的苯并呋喃衍生物：其中x是式：—N═或—CH═的基团；Y是可选取代的氨基基团、可选取代的环烷基团或可选取代的饱和杂环基团；A是单键、具有双键的碳链（可在链的内部或端部）或氧原子；R1是氢原子或卤原子；环B是可选取代的苯环；R3是氢原子或其药学上可接受的盐，其作为药物特别是作为激活的血凝因子X抑制剂有用。